Literature DB >> 165518

Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

E Svedmyr, M Jondal.   

Abstract

Peripheral lymphoid cells, from 12 cases of acute infectious mononucleosis (IM), were tested in a micro chromium-51 release assay for cytotoxic activity against a variety of cell lines that did or did not carry the Epstein-Barr virus (EBV) genome. Unfractionated lymphocytes from these patients were cytotoxic to both types of cell lines, as were lymphocytes from healthy individuals. If, however, lymphocytes bearing complement receptors were removed, the residual IM lymphocyte fraction was specifically cytotoxic for EBV-genome-carrying cell lines. The residual lymphocyte fraction in normal donors had no such effect. Heterophile-positive IM is caused by EBV, and these results indicate that, during the acute phase of this disease, patients harbor killer cells, probably T cells, which specifically kill EBV-genome-carrying B cells in vitro. No such specificity for EBV-genome-psitive target cells was found in normal lymphocytes stimulated in vitro with autologous EBV-genome-positive lymphoblastoid cells. Such stimulated cells were highly cytotoxic to both genome-positive and negative lines after removal of complement receptor-positive lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165518      PMCID: PMC432591          DOI: 10.1073/pnas.72.4.1622

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA.

Authors:  G E FOLEY; H LAZARUS; S FARBER; B G UZMAN; B A BOONE; R E MCCARTHY
Journal:  Cancer       Date:  1965-04       Impact factor: 6.860

2.  Lymphocytes in infectious mononucleosis. Properties of atypical cells and origin on the lymphoblastoid lines.

Authors:  J Yata; C Desgranges; G de Thé; T Tachibana
Journal:  Biomedicine       Date:  1973-11-20

3.  Control mechanisms in infectious mononucleosis.

Authors:  A M Denman; B K Pelton
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

4.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  Sensitization of human lymphocytes against autologous or allogeneic lymphoblastoid cell lines: characteristics of the reactive cells.

Authors:  E Svedmyr; H Wigzell; M Jondal
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

6.  Establishment and characteristics of two unique cell lines from patients with lymphosarcoma.

Authors:  K Nilsson; C Sundström
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

7.  A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

8.  Cytotoxicity of a factor isolated from human spleen.

Authors:  C B Lozzio; B B Lozzio
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

Review 9.  T cell response to viral and bacterial infection.

Authors:  R V Blanden
Journal:  Transplant Rev       Date:  1974

10.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

View more
  104 in total

Review 1.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

2.  Antigenic content of an in vitro cellular immunity reactive cell surface extract of Raji cells.

Authors:  M H Ng; W S Ng; H C Ho
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

3.  In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.

Authors:  G Strang; A B Rickinson
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

4.  Expression of CD45R0 (UCHL1) by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis.

Authors:  T Miyawaki; Y Kasahara; H Kanegane; K Ohta; T Yokoi; A Yachie; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

6.  Inhibition of the in vitro outgrowth of Epstein-Barr virus-transformed lymphocytes by thymus-dependent lymphocytes from infectious mononucleosis patients.

Authors:  A B Rickinson; D Crawford; M A Epstein
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

7.  Surface glycoproteins of resting and activated human T lymphocytes.

Authors:  L C Andersson; C G Gahmberg
Journal:  Mol Cell Biochem       Date:  1979-10-15       Impact factor: 3.396

8.  Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line.

Authors:  V van Santen; A Cheung; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Spontaneous cytotoxicity of rheumatoid and normal peripheral blood mononuclear cells against 4 human lymphoblastoid cell lines.

Authors:  J Highton; G S Panayi
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

10.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.